Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.45M | -17.43M | -5.66M | -9.47M | -369.60K |
| Total Depreciation and Amortization | 663.00K | 662.90K | 662.60K | 662.90K | 662.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.49M | 2.22M | 3.70M | 7.43M | 280.80K |
| Change in Net Operating Assets | -4.05M | -2.60M | -1.06M | 2.10M | -496.80K |
| Cash from Operations | -12.35M | -17.15M | -2.36M | 715.70K | 77.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18.52M | 18.82M | 19.44M | 4.78M | 1.53M |
| Repurchase of Common Stock | -600.00K | -- | -- | -400.00 | -400.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -200.00K | 338.90K | 227.70K | 0.00 |
| Cash from Financing | 17.92M | 18.62M | 19.78M | 5.01M | 1.53M |
| Foreign Exchange rate Adjustments | 14.00K | 852.60K | 410.50K | -161.60K | -3.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.58M | 2.32M | 17.83M | 5.56M | 1.60M |